Skip to main content

Frontline Combinations Better Survival Rates in EGFRm Lung Cancer

*November 2023*

First-line combination treatment regimens are improving progression-free survival (PFS) rates in patients with EGFR-mutated non–small cell lung cancer (NSCLC), according to Julia Rotow, MD.1

Prior to November 2023, the main first-line therapy utilized for the treatment of patients with EGFR-mutated lung cancer was osimertinib (Tagrisso) monotherapy, based on the phase 3 FLAURA study (NCT02296125). In FLAURA, treatment with osimertinib was superior compared with standard EGFR-tyrosine kinase inhibitors (TKIs) and a similar safety profile was observed with lower rates of serious adverse events (AEs).

In 2018, the FDA expanded the approval of afatinib (Gilotrif) for patients with metastatic NSCLC who harbor EGFR mutations as detected by an FDA-approved test.1 This approval was based on findings from 3 clinical trials (LUX-Lung 2 [NCT00525148], LUX-Lung 3 [NCT00949650], and LUX-Lung 6 [NCT01121393]), which showed that durable responses were observed in a subset of 32 patients with metastatic NSCLC harboring non-resistant EGFR mutations who were treated with afatinib (S768I, L861Q, and/or G719X), other than exon 19 deletions or exon 21 L858R substitutions.

However, the treatment landscape has expanded within the past 2 months with new data presented at the European Society for Medical Oncology (ESMO) Congress 2023.

Rotow, a medical oncologist at the Dana-Farber Cancer Institute, discussed these impactful and emerging data on upfront therapies for patients with lung cancer harboring EGFR mutations in a presentation titled, “EGFR – Can We Do Better Upfront?”, at the 18th Annual New York Lung Cancers Symposium. Read more.